State Street reports 5.2% stake in BEAM Therapeutics
State Street Corporation has filed a Schedule 13G reporting a passive ownership stake in BEAM Therapeutics Inc. common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
State Street Corporation has filed a Schedule 13G reporting a passive ownership stake in BEAM Therapeutics Inc. common stock. As of 12/31/2025, it beneficially owned 5,228,529 shares, representing 5.2% of the outstanding common stock.
State Street reports shared voting power over 4,949,918 shares and shared dispositive power over 5,228,529 shares, with no sole voting or dispositive power. The filing is certified as being made in the ordinary course of business and not for the purpose of influencing control of BEAM Therapeutics.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does State Street Corporation report in BEAM Therapeutics (BEAM)?
Is State Street’s BEAM Therapeutics (BEAM) holding reported as passive or active?
What dispositive power does State Street report over BEAM Therapeutics (BEAM) stock?
Which State Street affiliates are linked to the BEAM Therapeutics (BEAM) holdings?
Why did State Street file this Schedule 13G for BEAM Therapeutics (BEAM)?
AI-generated analysis. How Rhea-AI works. Not financial advice.